Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effect of GTX-102 in cognitive function in participants with deletion-type Angelman Syndrome (AS).